Researchers used a 3+3 dose de-escalation design in a safety run-in period to evaluate two lenvatinib doses — 12 mg daily or 16 mg daily — combined with 10 mg/kg IV cadonilimab every 3 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback